1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray
F. Global Cancer statistics for the year 2020: an overview. Int J Cancer. 2021.
https://doi.org/10.1002/ijc.33588
2. Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, Sharif
M, Khatibian M, Fitzmaurice C, Nixon MR, et al. The global, regional, and
national burden of pancreatic cancer and its attributable risk factors in 195
countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47.
3. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med.
2014;371(11):1039–49.
4. Cancer Genome Atlas Research Network. Electronic address aadhe, Cancer
Genome Atlas Research N: Integrated genomic characterization of pancreatic
ductal adenocarcinoma. Cancer Cell. 2017;32(2):185–203. e113.
5. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al. Maintenance olaparib for germline BRCAMutated metastatic pancreatic Cancer. N Engl J Med. 2019;381(4):317–27.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa
P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial
of the National Cancer Institute of Canada clinical trials Group. J Clin Oncol.
2007;25(15):1960–6.
7. Malinova A, Veghini L, Real FX, Corbo V. Cell lineage infidelity in PDAC progression and Therapy Resistance. Front Cell Dev Biol. 2021;9:795251.
8. Yamakawa K, Koyanagi-Aoi M, Uehara K, Masuda A, Yanagimoto H, Toyama H,
Fukumoto T, Kodama Y, Aoi T. Increased expression of SPRR1A is associated
with a poor prognosis in pancreatic ductal adenocarcinoma. PLoS ONE.
2022;17(5):e0266620.
9. Koterazawa Y, Koyanagi-Aoi M, Uehara K, Kakeji Y, Aoi T. Retinoic acid receptor
gamma activation promotes differentiation of human induced pluripotent
stem cells into esophageal epithelium. J Gastroenterol. 2020;55(8):763–74.
10. di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C,
Lo-Coco F, Ascenzi P, Nervi C. Retinoic acid receptors: from molecular mechanisms to cancer therapy. Mol Aspects Med. 2015;41:1–115.
11. Mohammad Sultan KMC. Retinoid Signaling in Cancer and its Promise for
Therapy. J Carcinog Mutagen. 2013. https://doi.org/10.4172/2157-2518.
S7-006
12. Colvin EK, Susanto JM, Kench JG, Ong VN, Mawson A, Pinese M, Chang DK,
Rooman I, O’Toole SA, Segara D, et al. Retinoid signaling in pancreatic cancer,
injury and regeneration. PLoS ONE. 2011;6(12):e29075.
13. Bleul T, Ruhl R, Bulashevska S, Karakhanova S, Werner J, Bazhin AV. Reduced
retinoids and retinoid receptors’ expression in pancreatic cancer: a link to
patient survival. Mol Carcinog. 2015;54(9):870–9.
Yamakawa et al. Cancer Cell International
(2023) 23:94
14. Leelawat K, Ohuchida K, Mizumoto K, Mahidol C, Tanaka M. All-trans
retinoic acid inhibits the cell proliferation but enhances the cell invasion
through up-regulation of c-met in pancreatic cancer cells. Cancer Lett.
2005;224(2):303–10.
15. Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, de Wilde
RF, Hong SM, Goggins MG, De Jesus-Acosta A, Laheru D, et al. Molecular
determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res.
2012;18(1):280–9.
16. Moore DF Jr, Pazdur R, Sugarman S, Jones D 3rd, Lippman SM, Bready B,
Abbruzzese JL. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha
combination therapy for advanced pancreatic adenocarcinoma. Am J Clin
Oncol. 1995;18(6):525–7.
17. Michael A, Hill M, Maraveyas A, Dalgleish A, Lofts F. 13-cis-retinoic acid in
combination with gemcitabine in the treatment of locally advanced and
metastatic pancreatic cancer–report of a pilot phase II study. Clin Oncol (R
Coll Radiol). 2007;19(2):150–3.
18. Polvani S, Tarocchi M, Tempesti S, Galli A. Nuclear receptors and pathogenesis
of pancreatic cancer. World J Gastroenterol. 2014;20(34):12062–81.
19. Kaiser A, Herbst H, Fisher G, Koenigsmann M, Berdel WE, Riecken EO, Rosewicz S. Retinoic acid receptor beta regulates growth and differentiation in
human pancreatic carcinoma cells. Gastroenterology. 1997;113(3):920–9.
20. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg
J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, et al. Analysis of
the human tissue-specific expression by genome-wide integration of
transcriptomics and antibody-based proteomics. Mol Cell Proteomics.
2014;13(2):397–406.
21. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A,
Sivertsson A, Kampf C, Sjostedt E, Asplund A et al. Proteomics. Tissue-based
map of the human proteome. Science 2015, 347(6220):1260419.
22. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo
MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines.
Pancreas. 2010;39(4):425–35.
23. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd,
Barretina J, Gelfand ET, Bielski CM, Li H, et al. Next-generation characterization
of the Cancer Cell Line Encyclopedia. Nature. 2019;569(7757):503–8.
24. Uehara K, Koyanagi-Aoi M, Koide T, Itoh T, Aoi T. Epithelial-derived factors
induce muscularis mucosa of human induced pluripotent stem cell-derived
gastric organoids. Stem Cell Reports. 2022;17(4):820–34.
25. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of
image analysis. Nat Methods. 2012;9(7):671–5.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment
analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
27. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid
Res. 2002;43(11):1773–808.
28. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo
P, Carter H, Kamiyama H, Jimeno A, et al. Core signaling pathways in
human pancreatic cancers revealed by global genomic analyses. Science.
2008;321(5897):1801–6.
29. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase
cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47.
30. Chesnokov MS, Khan I, Park Y, Ezell J, Mehta G, Yousif A, Hong LJ, Buckanovich
RJ, Takahashi A, Chefetz I. The MEK1/2 Pathway as a Therapeutic Target in
High-Grade Serous Ovarian Carcinoma. Cancers (Basel) 2021, 13(6).
31. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour
development: friend or foe? Nat Rev Cancer. 2004;4(12):966–77.
32. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with
nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.
33. Huang GL, Luo Q, Rui G, Zhang W, Zhang QY, Chen QX, Shen DY. Oncogenic
activity of retinoic acid receptor gamma is exhibited through activation of
Page 15 of 15
34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. the Akt/NF-kappaB and Wnt/beta-catenin pathways in cholangiocarcinoma.
Mol Cell Biol. 2013;33(17):3416–25.
Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, Zhou H, Li WG, Cao X, Lin YY, et
al. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular
carcinoma. Cancer Res. 2010;70(6):2285–95.
Huang GL, Song W, Zhou P, Fu QR, Lin CL, Chen QX, Shen DY. Oncogenic
retinoic acid receptor gamma knockdown reverses multi-drug resistance
of human colorectal cancer via Wnt/beta-catenin pathway. Cell Cycle.
2017;16(7):685–92.
Ji K, Dou W, Zhang N, Wen B, Zhong M, Zhang Q, Xu S, Zhou J, Liu J. Retinoic
acid receptor gamma is required for proliferation of pancreatic cancer cells.
Cell Biol Int. 2022;47(1):144–55.
Brown G, Petrie K. The RARgamma Oncogene: an Achilles Heel for some
cancers. Int J Mol Sci. 2021;22(7):3632.
Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of
advanced oestrogen-receptor-positive breast cancer. The Lancet.
2017;389(10087):2403–14.
Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA,
McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patientderived models of pancreatic cancer. Oncotarget. 2015;6(18):15788–801.
Heilmann AM, Perera RM, Ecker V, Nicolay BN, Bardeesy N, Benes CH, Dyson
NJ. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of
p16INK4A-deficient pancreatic cancers. Cancer Res. 2014;74(14):3947–58.
Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities. World J Gastroenterol.
2021;27(39):6527–50.
McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL,
Force T, Koch WJ, Knudsen ES. CDK4/6 inhibition antagonizes the cytotoxic
response to anthracycline therapy. Cell Cycle. 2012;11(14):2747–55.
Salvador-Barbero B, Alvarez-Fernandez M, Zapatero-Solana E, El Bakkali A,
Menendez MDC, Lopez-Casas PP, Di Domenico T, Xie T, VanArsdale T, Shields
DJ, et al. CDK4/6 inhibitors impair recovery from cytotoxic chemotherapy in
pancreatic adenocarcinoma. Cancer Cell. 2020;37(3):340–353e346.
Li Q, Yin L, Jones LW, Chu GC, Wu JB, Huang JM, Li Q, You S, Kim J, Lu YT, et
al. Keratin 13 expression reprograms bone and brain metastases of human
prostate cancer cells. Oncotarget. 2016;7(51):84645–57.
Zhang Z, Tu K, Liu F, Liang M, Yu K, Wang Y, Luo Y, Yang B, Qin Y, He D, et al.
FoxM1 promotes the migration of ovarian cancer cell through KRT5 and
KRT7. Gene. 2020;757:144947.
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens
LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding
the tumor immune microenvironment (TIME) for effective therapy. Nat Med.
2018;24(5):541–50.
Vonlaufen A, Phillips PA, Xu Z, Goldstein D, Pirola RC, Wilson JS, Apte MV. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer
Res. 2008;68(19):7707–10.
Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H,
Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence
reduces paracrine wnt-beta-catenin signaling to slow tumor progression.
Gastroenterology. 2011;141(4):1486–97. 1497 e1481-1414.
Guan J, Zhang H, Wen Z, Gu Y, Cheng Y, Sun Y, Zhang T, Jia C, Lu Z, Chen J.
Retinoic acid inhibits pancreatic cancer cell migration and EMT through
the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett.
2014;345(1):132–9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
...
論文の公開元へ
